Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Will Genentech's Cotellic Survive Alternative Pricing Demands?

This article was originally published in Scrip

Executive Summary

Genentech Inc.'s and Exelixis Inc.'s Cotellic (cobimetinib), a MEK inhibitor, made it across the FDA's finish line on Nov. 10, but now the firms must confront the ultimate test of the drug's success – selling it, which is increasingly becoming more difficult in a climate where payers are becoming more and more demanding about using alternative pricing arrangements.


Related Content

Array Rises As COLUMBUS Clears Phase III Melanoma Hurdle


Related Companies